News
Positive results for Evgen’s rhabdomyosarcoma therapy
Evgen Pharma has issued an update on its research partnership with Sapienza University of Rome, which has been concentrating on the radiosensitising impact of SFX-01 in-vivo when treating rhabdomyosarcoma (RMS).